Administration of tetrandrine (50 mg·kg-1·d-1, i.g., for 15 days) significantly suppressed melanoma growth in mouse models accompanied by increased CD8+ T cell infiltration and activation within the tumor microenvironment. This evidence concerns the gene CD8A and melanoma.